Brian Kaspar (via Twitter)
March 29, 2021 09:00 AM EDTUpdated April 2, 04:09 AM
People

Look­ing to leave Zol­gens­ma da­ta ma­nip­u­la­tion scan­dal be­hind, Bri­an Kas­par emerges at a new gene ther­a­py play­er

Nicole DeFeudis

Editor

A year af­ter get­ting blamed by No­var­tis for a da­ta ma­nip­u­la­tion scan­dal over its cost­ly gene ther­a­py Zol­gens­ma, Bri­an Kas­par has turned up on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times